Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer
Prostate Cancer
DRUG: Zoledronic acid
To assess the activity of one year treatment with zoledronic acid, 12 mos
Three-year disease free survival, 3 years|Change in bone mineral density at 12, 24 and 36 months versus baseline, 12, 24 and 36 months|Changes in bone resorption markers at 12, 24 and 36 months versus baseline, 12, 24 and 36 months|Safety and tolerability through abnormal values and AE reporting, upto 36 mos
The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer